Gyermekkori daganatok: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 98
• TP53 8
• PD-1 24
• MYCN 0
• ALK 13
• CD22 30
• BRAF 12
• ABL1 2
• NF1 12
• HER2 25
• PI3K 5
• AKT 1
• PD-L1 13
• CDK4/6 7
• NTRK 10
• NMDA 0
• B7-H3 15
• mTOR 2
• RB1 1
• PSMA 20
• KMT2A 12
• MEK 7
• FLT3 6
• MAPK 5
• CD30 8
• RUNX1 3
• VEGF 5
• IDH 6
• MYC 1
• RET 4
• CD20 12
• ERK 0
• PTEN 2
• CD123 10
• NPM1 9
• EGFR 2
• CTNNB1 2
• FGFR 3
• STAT3 0
• BRCA1 1
• BCL-2 2
• KIT 3
• ROS1 9
• CD33 7
• NRF2 0
• PARP 6
• PPAR 0
• YAP 0
• CD38 5
• EZH2 0
• RAS 1
• JAK 4
• JNK 0
• SNCA 0
• BRCA2 2
• CTLA-4 4
• KRAS 3
• MET 4
• NRAS 0
• VHL 5

19+ intézményből 19, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL

  NCT06985498· The First Affiliated Hospital of Soochow University· Frissítve: 2026. máj. 29.

  “According to the new regulations of China, newly launched clinical trials involved CAR-T cells must be apporved first by China National Center for Biotechology Development.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

  NCT07093086· Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd· Frissítve: 2026. máj. 6.

  “The primary consideration is the allocation of company resources, and we have no choice but to terminate this research.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

  NCT03913559· St. Jude Children's Research Hospital· Frissítve: 2026. febr. 12.

  “Closed due to slow accrual”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

  NCT03098355· Zhujiang Hospital· Frissítve: 2024. márc. 18.

  “The company did not offer the appropriate CART services.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia

  NCT05168748· Novartis Pharmaceuticals· Frissítve: 2022. dec. 21.

  “Sponsor's decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

  NCT03226704· National Cancer Institute (NCI)· Forrás

• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  NCT05442515· National Cancer Institute (NCI)· Forrás

• CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

  NCT07328503· National Cancer Institute (NCI)· Forrás

• Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  NCT07109219· AstraZeneca· Forrás

• CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

  NCT05470777· The First Affiliated Hospital of Soochow University· Forrás

• Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

  NCT02315612· National Cancer Institute (NCI)· Forrás

• Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

  NCT03913559· St. Jude Children's Research Hospital· Forrás

• A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

  NCT07135466· Sheba Medical Center· Forrás

• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

  NCT03448393· National Cancer Institute (NCI)· Forrás

• CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

  NCT06834529· Affiliated Hospital to Academy of Military Medical Sciences· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 38
• Organoids 15
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 15
• Gene Expression Profiling 125
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 22
• Exome Sequencing 31
• Proteomics 52
• Metabolomics 25
• Mass Spectrometry 13
• Flow Cytometry 87
• Immunohistochemistry 197
• Liquid Biopsy 25
• Circulating Tumor DNA 15
• Xenograft Model Antitumor Assays 134
• Positron-Emission Tomography 52
• Magnetic Resonance Imaging 520
• Machine Learning 67
• Deep Learning 25
• Cohort Studies 328
• Genome-Wide Association Study 22

• Early Prediction of Cardiomyopathy in Pediatric Cancer Survivors Using Echocardiographic Video-Based Deep Learning.

  Echocardiography, 2026. okt.

• [Multicenter study of deep learning multitask model for predicting neoadjuvant chemotherapy response and event-free survival of pediatric head and neck rhabdomyosarcoma].

  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2026. szept.

• Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy.

  Signal Transduct Target Ther, 2026. aug.

• TFE3-DualNet: An Interpretable Foundation Model-Based Deep Learning Ensemble for Diagnosing TFE3-Rearranged Renal Cell Carcinoma From Whole-Slide Images in a Two-Center Cohort.

  Cancer Med, 2026. aug.

• Deep learning-based automated segmentation of target volumes for pediatric craniospinal irradiation in proton therapy.

  Radiat Oncol, 2026. júl.

• Deep learning for contrast-enhanced MRI in pediatric brain imaging.

  Neuroradiology, 2026. júl.

• The role of machine learning, deep learning, and MRI findings in the classification of pediatric posterior fossa tumors.

  Childs Nerv Syst, 2026. jún.

• Improving image quality and diagnostic confidence for PRETEXT staging in pediatric hepatoblastoma using thin-slice and low-energy virtual monochromatic images in dual-energy CT with deep learning image reconstruction algorithm.

  BMC Med Imaging, 2026. máj.

• A novel deep-learning approach for monitoring gastrointestinal air variation during radiotherapy in young patients using radiographs.

  Phys Med Biol, 2026. máj.

• Deep Learning-Based Analysis of Gene Expression Data and Gene-Related Information in Pediatric Surgical Oncology: A Scoping Review.

  Cancer Med, 2026. máj.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.